Indication
Colon Adenocarcinoma
7 clinical trials
8 products
3 drugs
Clinical trial
3T: A Phase II Single Arm Open Label Study of Tucatinib Combined With Trastuzumab and TAS-102 in Molecularly Selected Patients With HER2+ Metastatic Colorectal CancerStatus: Not yet recruiting, Estimated PCD: 2024-05-30
Drug
TrastuzumabProduct
Trifluridine and TipiracilDrug
TucatinibClinical trial
A Phase I Clinical Trial of Regorafenib, Nivolumab, and Ipilimumab in Advanced Chemotherapy Resistant Metastatic MSS Colorectal CancerStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Product
IpilimumabProduct
NivolumabDrug
RegorafenibClinical trial
Phase Ib/II Trial of SX-682 in Combination With Nivolumab for Refractory RAS Mutated (RAS) Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC) (STOPTRAFFIC-1)Status: Recruiting, Estimated PCD: 2025-01-31
Product
SX-682Clinical trial
Phase I/II Trial of Encorafenib, Cetuximab, and Nivolumab in Microsatellite Stable BRAFV600E Metastatic Colorectal Cancer (BMS-MDACC CA209-8P6/ARRAY IST-818-101X)Status: Recruiting, Estimated PCD: 2025-06-30
Product
CetuximabProduct
EncorafenibClinical trial
Randomized Phase II Trial of Encorafenib and Cetuximab With or Without Nivolumab (NSC #748726) for Patients With Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal CancerStatus: Recruiting, Estimated PCD: 2024-08-31
Clinical trial
A Phase 2 Study of Savolitinib in Subjects With MET Amplified Metastatic Colorectal CancerStatus: Terminated, Estimated PCD: 2021-07-31
Product
SavolitinibClinical trial
PULSE: A Randomized, Phase II Open Label Study of PanitUmumab RechaLlenge Versus Standard Therapy After Progression on Anti-EGFR Therapy in Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal CancerStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Product
Panitumumab